Dysregulation of purine nucleotide biosynthesis pathways modulates cisplatin cytotoxicity in Saccharomyces cerevisiaem

Molecular Pharmacology

Volumn 74, Issue 4, 2008, Pages 1092-1100

  Kowalski, David ^a   Pendyala, Lakshmi ^a   Daignan Fornier, Bertrand ^b   Howell, Stephen B ^c   Huang, Ruea Yea ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ADENOSINE PHOSPHATE; CISPLATIN; CYTOSINE; DOXORUBICIN; FLUOROURACIL; GUANINE; GUANOSINE PHOSPHATE; GUANYLATE KINASE; HYPOXANTHINE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MUTANT PROTEIN; PERMEASE; PROTEIN FCY2; PURINE CYTOSINE PERMEASE; PURINE NUCLEOTIDE; UNCLASSIFIED DRUG;

ADE4 GENE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA BINDING; DRUG CYTOTOXICITY; DRUG RESISTANCE; FCY2 GENE; GENE; GENE INACTIVATION; GENE OVEREXPRESSION; HPT1 GENE; MUTATOR GENE; NEGATIVE FEEDBACK; NONHUMAN; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; WILD TYPE; YEAST CELL;

EID: 52949124380     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.048256     Document Type: Article

References (41)

1. Albain KS, Swinnen LJ, Erickson LC, Stiff PJ, Fisher SG, and Fisher RI (1992) Cytotoxic synergy of cisplatin with concurrent hydroxyurea and cytarabine: summary of an in vitro model and initial clinical pilot experience. Semin Oncol 19:102-109.
2. Ali MS, Khan SR, Ojima H, Guzman IY, Whitmire KH, Siddik ZH, and Khokhar AR (2005) Model platinum nucleobase and nucleoside complexes and antitumor activity: X-ray crystal structure of [PtIV(trans-1R,2R- diaminocyclohexane)trans-(acetate)2(9-ethylguanine)Cl]NO 3.H2O. J Inorg Biochem 99:795-804.
3. Baik MH, Friesner RA, and Lippard SJ (2003) Theoretical study of cisplatin binding to purine bases: why does cisplatin prefer guanine over adenine? J Am Chem Soc 125:14082-14092.
4. 1 receptor in the rat kidney. Eur J Pharmacol 442:251-264.
5. Broach JR, Strathern JN, and Hicks JB (1979) Transformation in yeast: development of a hybrid cloning vector and isolation of the CAN1 gene. Gene 8:121-133.
6. Chaney SG, Campbell SL, Bassett E, and Wu Y (2005) Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 53:3-11.
7. Collins A and Oates DJ (1987) Hydroxyurea: effects on deoxyribonucleotide pool sizes correlated with effects on DNA repair in mammalian cells. Eur J Biochem 169:299-305.
8. Crowley JC and Kaback DB (1984) Molecular cloning of chromosome I DNA from Saccharomyces cerevisiae: isolation of the ADE1 gene. J Bacteriol 159:413-417.
9. Denis V, Boucherie H, Monribot C, and Daignan-Fornier B (1998) Role of the myb-like protein bas1p in Saccharomyces cerevisiae: a proteome analysis. Mol Microbiol 30:557-566.
10. Di Pasqua AJ, Goodisman J, Kerwood DJ, Toms BB, Dubowy RL, and Dabrowiak JC (2007) Role of carbonate in the cytotoxicity of carboplatin. Chem Res Toxicol 20:896-904.
11. Durant ST, Morris MM, Illand M, McKay HJ, McCormick C, Hirst GL, Borts RH, and Brown R (1999) Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes. Curr Biol 9:51-54.
12. Escobar-Henriques M and Daignan-Fornier B (2001) Transcriptional regulation of the yeast GMP synthesis pathway by its end products. J Biol Chem 276:1523-1530.
13. Frańska M, Frański R, Schroeder G, Springer A, Beck S, and Linscheid M (2005) Electrospray ionization mass spectrometric study of purine base-cisplatin complexes. Rapid Commun Mass Spectrom 19:970-974.
14. Furuchi T, Ishikawa H, Miura N, Ishizuka M, Kajiya K, Kuge S, and Naganuma A (2001) Two nuclear proteins, Cin5 and Ydr259c, confer resistance to cisplatin in Saccharomyces cerevisiae. Mol Pharmacol 59:470-474.
15. Gercel-Taylor C, Scobee JJ, and Taylor DD (2005) Effect of chemotherapy on the mutation frequency of ovarian cancer cells at the HPRT locus. Anticancer Res 25:2113-2117.
16. Guetsova ML, Lecoq K, and Daignan-Fornier B (1997) The isolation and characterization of Saccharomyces cerevisiae mutants that constitutively express purine biosynthetic genes. Genetics 147:383-397.
17. Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S, and Pendyala L (2001) In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol 48:398-406.
18. Holzer AK and Howell SB (2006) The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res 66:10944-10952.
19. Huang RY, Eddy M, Vujcic M, and Kowalski D (2005) Genome-wide screen identifies genes whose inactivation confer resistance to cisplatin in Saccharomyces cerevi-siae. Cancer Res 65:5890-5897.
20. Ishikawa T and Ali-Osman F (1993) Glutathione-associated cis-diamminedichloro-platinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem 268:20116-20125.
21. Jansen BA, Brouwer J, and Reedijk J (2002) Glutathione induces cellular resistance against cationic dinuclear platinum anticancer drugs. J Inorg Biochem 89:197-202.
22. Kerr SL, Shoeib T, and Sharp BL (2008) A study of oxaliplatin-nucleobase interactions using ion trap electrospray mass spectrometry. Anal Bioanal Chem 391: 2339-2348.
23. Koehler RN, Rachfall N, and Rolfes RJ (2007) Activation of the ade genes requires the chromatin remodeling complexes saga and swi/snf. Eukaryot Cell 6:1474-1485.
24. Lecoq K, Konrad M, and Daignan-Fornier B (2000) Yeast GMP kinase mutants constitutively express AMP biosynthesis genes by phenocopying a hypoxanthine-guanine phosphoribosyltransferase defect. Genetics 156:953-961.
25. Li G, Alexander H, Schneider N, and Alexander S (2000) Molecular basis for resistance to the anticancer drug cisplatin in Dictyostelium. Microbiology 146:2219-2227.
26. Mäntsälä P and Zalkin H (1984) Glutamine nucleotide sequence of Saccharomyces cerevisiae ADE4 encoding phosphoribosylpyrophosphate amidotransferase. J Biol Chem 259:8478-8484.
27. Martin DS, Spriggs D, and Koutcher JA (2001) A concomitant ATP-depleting strategy markedly enhances anticancer agent activity. Apoptosis 6:125-131.
28. Martinez P and Ljungdahl PO (2000) The SHR3 homologue from S. pombe demonstrates a conserved function of ER packaging chaperones J Cell Sci 113:4351-4362.
29. Niedner H, Christen R, Lin X, Kondo A, and Howell SB (2001) Identification of genes that mediate sensitivity to cisplatin. Mol Pharmacol 60:1153-1160.
30. Page T and Coleman M (2000) Purine metabolism abnormalities in a hyperuricosuric subclass of autism. Biochim Biophys Acta 1500:291-296.
31. Perez RP (1998) Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 34:1535-1542.
32. Rébora K, Desmoucelles C, Borne F, Pinson B, and Daignan-Fornier B (2001) Yeast AMP pathway genes respond to adenine through regulated synthesis of a metabolic intermediate. Mol Cell Biol 21:7901-7912.
33. Reedijk J and Lohman PH (1985) Cisplatin: synthesis, antitumour activity and mechanism of action. Pharm Weekbl Sci 7:173-180.
34. Rosenbloom FM (1968) Possible mechanism for increased purine biosynthesis de novo in Lesch-Nyhan syndrome. Fed Proc 27:1063-1066.
35. Sherman F (1991) Getting started with yeast. Methods Enzymol 194:3-21.
36. Shinohara A and Ogawa T (1998) Stimulation by Rad52 of yeast Rad51-mediated recombination. Nature 391:404-407.
37. Sigel RK, Thompson SM, Freisinger E, Glahé F, and Lippert B (2001) Metal-modified nucleobase sextet: joining four linear metal fragments (trans-a2PtII) and six model nucleobases to an exceedingly stable entity. Chemistry 7:1968-1980.
38. Van Driessche N, Alexander H, Min J, Kuspa A, Alexander S, and Shaulsky G (2007) Global transcriptional responses to cisplatin in Dictyostelium discoideum identify potential drug targets. Proc Natl Acad Sci U S A 104:15406-15411.
39. Yoshida M and Hoshi A (1984) Mechanism of inhibition of phosphoribosylation of 5-fluorouracil by purines. Biochem Pharmacol 33:2863-2867.
40. Zamble DB and Lippard SJ (1995) Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 20:435-439.
41. Zannis-Hadjopoulos M, Baumann EA, and Hand R (1980) Effect of purine deprivation on DNA synthesis and deoxyribonucleoside triphosphate pools of a mammalian purine auxotrophic mutant cell line. J Biol Chem 255:3014-3019.